Why Is ImmunityBio Stock Soaring On Friday?

Core Viewpoint - ImmunityBio Inc. has successfully completed its manufacturing engineering programs for its NK cell therapy platform, leading to a significant increase in its stock price. Group 1: NK Cell Therapy Development - The company has completed its NK2022 and NK2023 programs, which assessed the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy [1][2] - A total of 64 subjects participated in the trials, with no serious adverse events reported, demonstrating the safety of the therapy [2] - ImmunityBio can generate up to five billion NK cells from a single apheresis collection, allowing for the production of eight to ten therapeutic doses within 12 days [2][4] Group 2: Management Insights - Patrick Soon-Shiong, the founder and executive chairman, stated that the data shows the potential for scalable and safe manufacturing of NK cell therapy, which could provide a reliable source of potent NK cells [3] - The concept of creating a "World Bank of Natural Killer Cells" was introduced, suggesting that NK cells could be universally donated without HLA matching [4] Group 3: Regulatory Developments - The FDA has acknowledged receipt of ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aimed at treating BCG-unresponsive non-muscle invasive bladder cancer [5] - The resubmission follows ongoing discussions with the FDA that began in January 2026, with additional efficacy data submitted in March [5] Group 4: Analyst Consensus and Stock Performance - The stock currently holds a Buy rating with an average price target of $12.57, reflecting positive analyst sentiment [6] - Recent analyst actions include a Buy rating from BTIG with a target of $13 and D. Boral Capital maintaining a target of $23 [6] - ImmunityBio shares rose by 10.60% to $8.65 at the time of publication [6]